Jones Michael L 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Feb 19, 2020
Insider Transaction Report
Form 4
Jones Michael L
Exec. Director, Finance - PAO
Transactions
- Award
Emp. Stock Option (Right to Buy)
2020-02-14+4,900→ 4,900 totalExercise: $11.13From: 2020-02-14Exp: 2024-12-22→ Common Stock (4,900 underlying)
Footnotes (1)
- [F1]On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested.